Amalgamated Bank boosted its position in shares of FibroGen (NASDAQ:FGEN) by 12.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,489 shares of the biopharmaceutical company’s stock after acquiring an additional 1,066 shares during the quarter. Amalgamated Bank’s holdings in FibroGen were worth $450,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Carillon Tower Advisers Inc. bought a new position in shares of FibroGen in the fourth quarter valued at about $282,486,000. American International Group Inc. grew its stake in shares of FibroGen by 5.8% in the fourth quarter. American International Group Inc. now owns 46,949 shares of the biopharmaceutical company’s stock valued at $2,225,000 after acquiring an additional 2,588 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of FibroGen in the fourth quarter valued at about $739,000. Virtus Fund Advisers LLC acquired a new position in shares of FibroGen in the fourth quarter valued at about $405,000. Finally, UBS Asset Management Americas Inc. grew its stake in FibroGen by 18.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 257,485 shares of the biopharmaceutical company’s stock worth $12,205,000 after buying an additional 40,113 shares in the last quarter. 61.39% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on FGEN shares. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Finally, Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research note on Thursday, March 29th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $66.67.
In other FibroGen news, Director Roberto Pedro Rosenkranz sold 1,000 shares of FibroGen stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $52.34, for a total transaction of $52,340.00. Following the transaction, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $1,256,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $47.38, for a total transaction of $284,280.00. Following the transaction, the director now directly owns 28,000 shares in the company, valued at $1,326,640. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 427,799 shares of company stock valued at $22,937,028. Insiders own 13.60% of the company’s stock.
FibroGen stock traded down $0.10 during mid-day trading on Friday, hitting $44.90. 761,810 shares of the stock were exchanged, compared to its average volume of 517,031. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. FibroGen has a 12 month low of $24.25 and a 12 month high of $63.00. The firm has a market cap of $3,711.75, a price-to-earnings ratio of -25.95 and a beta of 1.89.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.01. The firm had revenue of $42.51 million during the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. equities research analysts predict that FibroGen will post -1.35 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Amalgamated Bank Increases Position in FibroGen (FGEN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/fibrogen-inc-fgen-shares-bought-by-amalgamated-bank.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.